Sign In
Buy RDY
$12.92
-0.270 (-2.05%)
At Close: Jul 13, 2026
Dr. Reddy's Laboratories Flags Semaglutide Supply Delay, Says No Recall Risk
05:02pm, Sunday, 12'th Jul 2026
Dr. Reddy's Laboratories NYSE: RDY said a scale-up issue tied to the active pharmaceutical ingredient for its semaglutide injection will temporarily delay commercial supplies, though management emphas
Dr. Reddy's Laboratories Limited (RDY) Discusses Manufacturing Issue and Process Review for Semaglutide Transcript
10:11am, Friday, 10'th Jul 2026
Dr. Reddy's Laboratories Limited (RDY) Discusses Manufacturing Issue and Process Review for Semaglutide Transcript
India's Torrent Pharma recalls select semaglutide pens after Dr. Reddy's notice
08:23am, Thursday, 09'th Jul 2026
Torrent Pharmaceuticals said on Thursday it was voluntarily recalling select batches of its Semalix semaglutide injection disposable pens after a product recall notifi
Dr. Reddy's Laboratories Limited Announces Filing of Annual Report on Form 20-F
11:10am, Friday, 26'th Jun 2026
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #AmericanDepositaryReceipts--Dr. Reddy's Laboratories Limited announces filing of Annual Report on Form 20-F.
Dr. Reddy's Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States
06:22am, Saturday, 13'th Jun 2026
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #Bosulif--Dr. Reddy's Laboratories Ltd. announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®
NYSE Content Update: Dell Technologies Reports 88% Revenue Increase YoY
08:55am, Friday, 29'th May 2026
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, May 29, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NY
Dr. Reddy's Launches Generic Semaglutide In Canada, Expands GLP-1 Push
03:17pm, Saturday, 16'th May 2026
Dr. Reddy's launched generic Semaglutide Injection in Canada, expanding its GLP-1 portfolio and strengthening its affordable diabetes treatment presence.
Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada
03:18am, Saturday, 16'th May 2026
HYDERABAD, India & MISSISSAUGA, Ontario--(BUSINESS WIRE)---- $RDY #DrReddy--Dr. Reddy's Laboratories Ltd. a global pharmaceutical company, today announced the launch of its generic Semaglutide Injecti
Dr. Reddy's Laboratories Q4 Earnings Call Highlights
08:12am, Thursday, 14'th May 2026
Dr. Reddy's Laboratories NYSE: RDY reported what Chief Financial Officer M.V. Narasimham described as a resilient FY 2026 performance, with record annual revenue despite pressure from lower lenalidomi
Dr. Reddy's Q4 Earnings and Revenues Miss Estimates, Stock Down
12:25pm, Wednesday, 13'th May 2026
RDY stock down 5% on missing fiscal fourth-quarter 2026 earnings and revenue estimates as North America generics sales slumped.
Dr. Reddy's Laboratories Limited (RDY) Q4 2026 Earnings Call Transcript
02:50pm, Tuesday, 12'th May 2026
Dr. Reddy's Laboratories Limited (RDY) Q4 2026 Earnings Call Transcript
Indian drugmaker Dr Reddy's posts quarterly profit slump
07:16am, Tuesday, 12'th May 2026
Indian drugmaker Dr Reddy's reported an 86% slump in quarterly profit on Tuesday, hurt by pricing pressure and increasing competition in its key U.S. market.
AMPH vs. RDY: Which Stock Should Value Investors Buy Now?
12:41pm, Wednesday, 29'th Apr 2026
Investors interested in stocks from the Medical - Generic Drugs sector have probably already heard of Amphastar Pharmaceuticals (AMPH) and Doctor Reddy's (RDY). But which of these two companies is the
Canada Approves Dr. Reddy's Generic Version of Novo Nordisk's Ozempic
12:37pm, Wednesday, 29'th Apr 2026
The country is the first in the G7 forum to approve a generic version of the massively popular GLP-1 diabetes treatment.
Dr. Reddy's Laboratories Announces Health Canada Approval for Generic Semaglutide Injection in Canada
07:38am, Wednesday, 29'th Apr 2026
HYDERABAD, India & MISSISSAUGA, Ontario--(BUSINESS WIRE)---- $RDY #DrReddy--Dr. Reddy's Laboratories Ltd. announced that it has received a Notice of Compliance (NOC) from Health Canada for its generic
